|
WO2021005500A1
|
|
Stable formulations of recombinant proteins
|
|
WO2020201975A2
|
|
Novel process for the preparation of filgotinib and intermediates thereof
|
|
WO2020194081A1
|
|
Extended release composition of tofacitinib
|
|
WO2020104911A1
|
|
Combination of chemotherapy with recombinant s. rolfsii lectin
|
|
CA3112250A1
|
|
Protein for treatment of inflammatory diseases
|
|
AU2019358330A1
|
|
An improved process for the preparation of recombinant lectin protein
|
|
WO2020044296A2
|
|
Recombinant lectin variants
|
|
WO2020026045A2
|
|
Leader sequence for higher expression of recombinant proteins
|
|
WO2019207443A1
|
|
An enzymatic process for the preparation of (r)-sitagliptin
|
|
WO2019123166A1
|
|
Nucleotide sequences encoding 3-quinuclidinone reductase and glucose dehydrogenase and soluble expression thereof
|
|
WO2019123066A1
|
|
Process for the preparation of opicapone and intermediates thereof
|
|
WO2019073331A2
|
|
Pharmaceutical compositions of apremilast
|
|
CN111065734A
|
|
Efficient enzymatic process for producing (R) -3-quinuclidinol
|
|
EP3668493A1
|
|
Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
|
|
WO2018203192A1
|
|
Novel process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4-yl]acetamide
|
|
WO2018154451A1
|
|
An improved process for preparation and purification of vortioxetine hydrobromide
|
|
EP3582759A1
|
|
Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
|
|
US2019358215A1
|
|
Pharmaceutical composition of apixaban
|
|
WO2018127762A1
|
|
An improved process for the preparation of rivaroxaban involving novel intermediate
|
|
WO2018060781A1
|
|
An improved process for the preparation of lacosamide
|
